Literature DB >> 9269876

Propofol pharmacokinetics and pharmacodynamics assessed from a cremophor EL formulation.

S Dutta, Y Matsumoto, W F Ebling.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9269876     DOI: 10.1021/js970118m

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


× No keyword cloud information.
  6 in total

1.  Preparation and anesthetic properties of propofol microemulsions in rats.

Authors:  Timothy E Morey; Jerome H Modell; Dushyant Shekhawat; Todd Grand; Dinesh O Shah; Nikolaus Gravenstein; Susan P McGorray; Donn M Dennis
Journal:  Anesthesiology       Date:  2006-06       Impact factor: 7.892

2.  Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan-10 after bolus injection.

Authors:  C A Knibbe; H J Voortman; L P Aarts; P F Kuks; R Lange; H J Langemeijer; M Danhof
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

3.  Pilot study in humans on the pharmacokinetics and safety of propofol 6% SAZN.

Authors:  C A Knibbe; V S Koster; L P Aarts; H J Langemeijer; M Danhof
Journal:  Pharm World Sci       Date:  1999-10

4.  Steroid Anesthesia Revisited: Again.

Authors:  Evan D Kharasch; Markus W Hollmann
Journal:  Anesth Analg       Date:  2015-05       Impact factor: 6.627

5.  Monitored anesthesia care (MAC) sedation: clinical utility of fospropofol.

Authors:  Eric A Harris; David A Lubarsky; Keith A Candiotti
Journal:  Ther Clin Risk Manag       Date:  2009-12-29       Impact factor: 2.423

6.  Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in Cremophor ® EL.

Authors:  Karl Henrik Johannes Ehinger; Magnus Joakim Hansson; Fredrik Sjövall; Eskil Elmér
Journal:  Clin Drug Investig       Date:  2013-01       Impact factor: 2.859

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.